Special Issue "Epigenetic Therapies and Biomarkers"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (31 July 2012)
Dr. Gordon Strathdee
Crucible Laboratory, Institute for Ageing and Health, Newcastle University, UK
Interests: epigenetics; DNA methylation; histone acetylation; Histone methylation; leukaemia; biomarkers; drug resistance
Dr. Philippe Bertrand
Institut de Chimie des Milieux et Matériaux de Poitiers, Université de Poitiers, CNRS-UMR 6514, 40 Avenue du Recteur Pineau, Poitiers, F-86022, France
Interests: chemistry for epigenetic targets; (asymetric) organic synthesis; click chemistry; drug delivery systems; organic functionalization of organic and inorganic materials
The last 15 years has seen a dramatic increase in our understanding of epigenetics, how epigenetic factors and enzymes regulate gene expression and how this can go awry during the development of disease. Much of this research has focussed on the development of cancer and it is now clear that epigenetic factors are crucial in the development of this disease. This understanding was swiftly followed by a major push to develop novel drugs and to re-examine known drugs for their ability to therapeutically target epigenetic changes. The first epigenetically targeted drugs are already approved for use in patients and many more are currently in clinical trials or pre-clinical development. With our ever increasing understanding of the many genes and pathways required for epigenetic regulation of the human genome the number of potential therapeutic targets for epigenetic therapies continues to rise.
Epigenetic changes also represent a potentially rich source of novel biomarkers, from potential uses in early diagnosis and screening to multiple studies showing links to prognosis or prediction of therapeutic responses. Epigenetic biomarkers are likely to play an important role in the increasing push towards personalised medicine and the rapid advancement in technologies for measuring epigenetic changes should allow increasingly sophisticated combinatorial approaches. Furthermore, there is increasing interest in the role of epigenetic changes as the basis not just for cancer, but for many other common chronic conditions and epigenetic changes associated with these conditions are already being identified. Consequently, it is likely that epigenetic based therapies and biomarkers are going to be of increasing medical importance.
Dr. Gordon Strathdee
Dr. Philippe Bertrand
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed Open Access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 500 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- DNA methylation
- Histone acetylation
- Histone methylation
Pharmaceuticals 2012, 5(1), 94-113; doi:10.3390/ph5010094
Received: 6 December 2011; in revised form: 10 January 2012 / Accepted: 11 January 2012 / Published: 18 January 2012| Download PDF Full-text (225 KB) | Download XML Full-text
Pharmaceuticals 2012, 5(4), 369-383; doi:10.3390/ph5040369
Received: 29 February 2012; in revised form: 23 March 2012 / Accepted: 27 March 2012 / Published: 5 April 2012| Download PDF Full-text (211 KB) | Download XML Full-text
Review: A Perspective on the Comparative Antileukemic Activity of 5-Aza-2′-deoxycytidine (Decitabine) and 5-Azacytidine (Vidaza)
Pharmaceuticals 2012, 5(8), 875-881; doi:10.3390/ph5080875
Received: 31 May 2012; in revised form: 16 August 2012 / Accepted: 17 August 2012 / Published: 21 August 2012| Download PDF Full-text (282 KB) | Download XML Full-text
Article: Differential Cellular and Molecular Effects of Butyrate and Trichostatin A on Vascular Smooth Muscle Cells
Pharmaceuticals 2012, 5(9), 925-943; doi:10.3390/ph5090925
Received: 21 July 2012; in revised form: 22 August 2012 / Accepted: 23 August 2012 / Published: 4 September 2012| Download PDF Full-text (1142 KB) | Download XML Full-text
Pharmaceuticals 2012, 5(9), 963-990; doi:10.3390/ph5090963
Received: 26 June 2012; in revised form: 21 July 2012 / Accepted: 17 August 2012 / Published: 12 September 2012| Download PDF Full-text (617 KB) | Download XML Full-text
Review: Strategies To Modulate Heritable Epigenetic Defects in Cellular Machinery: Lessons from Nature
Pharmaceuticals 2013, 6(1), 1-24; doi:10.3390/ph6010001
Received: 21 August 2012; in revised form: 20 November 2012 / Accepted: 18 December 2012 / Published: 27 December 2012| Download PDF Full-text (665 KB) | Download XML Full-text
Last update: 19 July 2013